A Phase 2/3 Study of Brepocitinib in Adults With Cutaneous Sarcoidosis

A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Cutaneous Sarcoidosis

This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with cutaneous sarcoidosis.

Inclusion Criteria:

1. Adults subjects
2. Cutaneous sarcoidosis with characteristic skin biopsy histology
3. A CSAMI activity score ≥ 10
4. Weight > 40 kg to < 130 kg, and with a body mass index (BMI) ≤ 45 kg/m2.

Exclusion Criteria

1. History of cancer, with the exception of the following cancers with documentation of complete resection and no evidence of recurrence for ≥ 1 year: basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ of the uterine cervix.
2. High risk of thrombosis or cardiovascular disease
3. High risk of herpes zoster
4. Active or recent infection